Publicaties
2023
Wetenschappelijke publicaties
Alsamil, A. M., Gardarsdottir, H., Leufkens, H. G., Egberts, T. C., & Giezen, T. J. (2023). Post-approval quality-related regulatory actions for biopharmaceuticals approved in the European Union and the United States between 1995 and 2019. Drug Discovery Today, 28(10), 103725. https://doi.org/10.1016/j.drudis.2023.103725
Kusynová, Z., van den Ham, H. A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2023). Pharmaceutical Scientists' Perspectives on Capacity Building in Pharmaceutical Sciences. Journal of Pharmaceutical Sciences, 112(7), 1997-2003. https://doi.org/10.1016/j.xphs.2023.04.015
Eskola, S. M., Leufkens, H. G. M., Bate, A., De Bruin, M. L., & Gardarsdottir, H. (2023). The role of Real-World Data and evidence in oncology medicines approved in EU in 2018-2019. Journal of Cancer Policy, 36, [100424]. https://doi.org/10.1016/j.jcpo.2023.100424
Wang, T., McAuslane, N., Goettsch, W. G., Leufkens, H. G. M., & De Bruin, M. L. (2023). Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement. International Journal of Technology Assessment in Health Care, 39(1), e20. https://doi.org/10.1017/S0266462323000144
2022
Wetenschappelijke publicaties
Postma, D. J., De Smet, P. A. G. M., Notenboom, K., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2022). Impact of medicine shortages on patients - a framework and application in the Netherlands. BMC Health Services Research, 22(1), 1-12. [1366]. https://doi.org/10.1186/s12913-022-08765-x
Kusynová, Z., van den Ham, H. A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2022). Longitudinal study of Good Pharmacy Practice roles covered at the annual world pharmacy congresses 2003–2019. Journal of Pharmaceutical Policy and Practice, 15(1), 1-14. [94]. https://doi.org/10.1186/s40545-022-00482-4
Costa, E., Cappellini, M. D., Rivella, S., Chilin, A., Alessi, E., Riccaboni, M., Leufkens, H. G. M., & Luzzatto, L. (2022). Emergent treatments for β-thalassemia and orphan drug legislations. Drug Discovery Today, 27(11), 1-13. [103342]. https://doi.org/10.1016/j.drudis.2022.103342
Wang, T., McAuslane, N., Goettsch, W. G., Leufkens, H. G. M., & De Bruin, M. L. (2022). Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile. Frontiers in Pharmacology, 13, 1-10. [948161]. https://doi.org/10.3389/fphar.2022.948161
Schoot, R. A., Otth, M. A., Frederix, G. W. J., Leufkens, H. G. M., & Vassal, G. (2022). Market access to new anticancer medicines for children and adolescents with cancer in Europe. European Journal of Cancer, 165, 146-153. https://doi.org/10.1016/j.ejca.2022.01.034
Costa, E., Girotti, S., Pauro, F., Leufkens, H. G. M., & Cipolli, M. (2022). The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet Journal of Rare Diseases, 17(1), 1-14. [188]. https://doi.org/10.1186/s13023-022-02350-5
Aguiar, J. P., Gama Marques, J., Leufkens, H. G. M., & Alves da Costa, F. (2022). Healthcare Professionals' Views on the Management of Medication Complexities in the Elderly With Mental Health Disorders: A Cross-Sectional Study. Frontiers in Psychiatry, 13, 1-8. [885216]. https://doi.org/10.3389/fpsyt.2022.885216
Alsamil, A. M., Giezen, T. J., Egberts, T. C., Doevendans, E., Leufkens, H. G., & Gardarsdottir, H. (2022). Nature and timing of post-approval manufacturing changes of tumour necrosis factor α inhibitor products: A 20-year follow-up study of originators and biosimilars. European Journal of Pharmaceutical Sciences, 175, 1-8. [106227]. https://doi.org/10.1016/j.ejps.2022.106227
Leung, M. W., Bazelier, M. T., Souverein, P. C., Uitdehaag, B. M., Klungel, O. H., Leufkens, H. G., & Pajouheshnia, R. (2022). Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum. Multiple sclerosis (Houndmills, Basingstoke, England), 28(11), 1808-1818. https://doi.org/10.1177/13524585221094218
Leufkens, H. G., Kusynová, Z., Aitken, M., Hoekman, J., Stolk, P., Klein, K., & Mantel-Teeuwisse, A. K. (2022). Four scenarios for the future of medicines and social policy in 2030. Drug Discovery Today, 27(8), 2252-2260. https://doi.org/10.1016/j.drudis.2022.03.018
Vreman, R. A., Strigkos, G., Leufkens, H. G. M., Schünemann, H. J., Mantel-Teeuwisse, A. K., & Goettsch, W. G. (2022). Addressing uncertainty in relative effectiveness assessments by HTA organizations. International Journal of Technology Assessment in Health Care, 38(1), 1-8. [e17]. https://doi.org/10.1017/S026646232100177X
ten Ham, R. M. T., Frederix, G. W. J., Wu, O., Goettsch, W., Leufkens, H. G. M., Klungel, O. H., & Hoekman, J. (2022). Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England. Value in Health, 25(3), 390-399. https://doi.org/10.1016/j.jval.2021.09.012
Bloem, L. T., Bot, R. E., Mantel-Teeuwisse, A. K., van der Elst, M. E., Sonke, G. S., Klungel, O. H., Leufkens, H. G. M., & Hoekman, J. (2022). Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: a comparison with standard approved cancer drugs. British Journal of Clinical Pharmacology, 88(5), 2169-2179. https://doi.org/10.1111/bcp.15141
Eskola, S. M., Leufkens, H. G. M., Bate, A., De Bruin, M. L., & Gardarsdottir, H. (2022). Use of Real World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019. Clinical Pharmacology and Therapeutics, 111(1), 310-320. https://doi.org/10.1002/cpt.2462
Kusynová, Z., Pauletti, G. M., van den Ham, H. A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2022). Unmet medical need as a driver for pharmaceutical sciences - a survey among scientists. Journal of Pharmaceutical Sciences, 111, 1318-1324. https://doi.org/10.1016/j.xphs.2021.10.002
Wang, T., McAuslane, N., Gardarsdottir, H., Goettsch, W. G., & Leufkens, H. G. M. (2022). Building HTA insights into the drug development plan: Current approaches to seeking early scientific advice from HTA agencies. Drug Discovery Today, 27(1), 347-353. https://doi.org/10.1016/j.drudis.2021.09.014
2021
Wetenschappelijke publicaties
van den Berg, S., de Visser, S., Leufkens, H. G. M., & Hollak, C. E. M. (2021). Drug Repurposing for Rare Diseases: A Role for Academia. Frontiers in Pharmacology, 12, [746987]. https://doi.org/10.3389/fphar.2021.746987
Mulder, J., Verjans, R., Verbaanderd, C., Pean, E., Weemers, J., Leufkens, H. G. M., Pignatti, F., de Boer, A., Voest, E. E., Stoyanova-Beninska, V. V., & Pasmooij, A. M. G. (2021). Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Frontiers in Medicine, 8, 1-5. [790782]. https://doi.org/10.3389/fmed.2021.790782
Narsai, K., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2021). Linking market authorizations of medicines with disease burden in South Africa. Journal of Pharmaceutical Policy and Practice, 14(1), 1-10. [33]. https://doi.org/10.1186/s40545-021-00314-x
Kibira, D., Asiimwe, C., Muwonge, M., van den Ham, H. A., Reed, T., Leufkens, H. G., & Mantel-Teeuwisse, A. K. (2021). Donor Commitments and Disbursements for Sexual and Reproductive Health Aid in Kenya, Tanzania, Uganda and Zambia. Frontiers in Public Health, 9, 1-12. [645499]. https://doi.org/10.3389/fpubh.2021.645499
Vreman, R. A., Geenen, J. W., Knies, S., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., & Goettsch, W. G. (2021). Comment on "Deterministic Sensitivity Analysis Under Ignorance". PharmacoEconomics, 39(10), 1199. https://doi.org/10.1007/s40273-021-01086-7
https://dspace.library.uu.nl/bitstream/handle/1874/413013/Vreman2021_Article_CommentOnDeterministicSensitiv.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/413013/Vreman2021_Article_CommentOnDeterministicSensitiv.pdf?sequence=1
Bloem, L. T., Karomi, M., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., & Mantel-Teeuwisse, A. K. (2021). Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle–a focus on benefits and risks. Expert Opinion on Drug Safety, 20(11), 1433-1442. https://doi.org/10.1080/14740338.2021.1952981
Meijboom, R. W., Gardarsdottir, H., Becker, M. L., de Groot, M. C. H., Movig, K. L. L., Kuijvenhoven, J., Egberts, T. C. G., Leufkens, H. G. M., & Giezen, T. J. (2021). Switching TNFα inhibitors: Patterns and determinants. Pharmacology Research and Perspectives, 9(4), 1-9. [e00843]. https://doi.org/10.1002/prp2.843
Broekhoff, T. F., Sweegers, C. C. G., Krijkamp, E. M., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Goettsch, W. G., & Vreman, R. A. (2021). Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios. Value in Health, 24(6), 759-769. https://doi.org/10.1016/j.jval.2020.09.021
Klein, K., Stolk, P., De Bruin, M. L., & Leufkens, H. (2021). Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines. Drug Discovery Today, 26(10), 2221-2225. https://doi.org/10.1016/j.drudis.2021.04.005
Bloem, L. T., Vreman, R. A., Peeters, N. W. L., Hoekman, J., van der Elst, M. E., Leufkens, H. G. M., Klungel, O. H., Goettsch, W. G., & Mantel-Teeuwisse, A. K. (2021). Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clinical and Translational Science, 14(4), 1566-1577. https://doi.org/10.1111/cts.13027
ten Ham, R. M. T., Nievaart, J. C., Hoekman, J., Cooper, R. S., Frederix, G. W. J., Leufkens, H. G. M., Klungel, O. H., Ovelgönne, H., Hoefnagel, M. H. N., Turner, M. L., & Mountford, J. C. (2021). Estimation of manufacturing development costs of cell-based therapies: a feasibility study. Cytotherapy, 23(8), 730-739. https://doi.org/10.1016/j.jcyt.2020.12.014
Alsamil, A. M., Giezen, T. J., Egberts, T. C., Leufkens, H. G., & Gardarsdottir, H. (2021). Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals, 69, 30-37. https://doi.org/10.1016/j.biologicals.2020.12.003
Alsamil, A. M., Giezen, T. J., Egberts, T. C., Leufkens, H. G., & Gardarsdottir, H. (2021). Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals (Basel, Switzerland), 14(3), 1-14. [189]. https://doi.org/10.3390/ph14030189
Kibira, D., Ooms, G. I., Van Den Ham, H. A., Namugambe, J. S., Reed, T., Leufkens, H. G. M., & Mantel-Teeuwisse, A. (2021). Access to oxytocin and misoprostol for management of postpartum haemorrhage in Kenya, Uganda and Zambia: A cross-sectional assessment of availability, prices and affordability. BMJ Open, 11(1), 1-8. [e042948]. https://doi.org/10.1136/bmjopen-2020-042948
Kibira, D., Ssebagereka, A., van den Ham, H. A., Opigo, J., Katamba, H., Seru, M., Reed, T., Leufkens, H. G., & Mantel-Teeuwisse, A. K. (2021). Trends in access to anti‐malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first‐line anti‐malarials and diagnostics between 2007 and 2018. Malaria Journal, 20(1), 1-8. [142]. https://doi.org/10.1186/s12936-021-03680-8
2020
Wetenschappelijke publicaties
Wang, T., Lipska, I., McAuslane, N., Liberti, L., Hövels, A., & Leufkens, H. (2020). Benchmarking health technology assessment agencies - Methodological challenges and recommendations. International Journal of Technology Assessment in Health Care, 36(4), 332-348. https://doi.org/10.1017/S0266462320000598
Leufkens, H. G. (2020). Regulatory science: Regulation is too important to leave it to the regulators. British Journal of Clinical Pharmacology, 86(12), 2333-2334. https://doi.org/10.1111/bcp.13917
Torre, C., Guerreiro, J., Longo, P., Raposo, J. F., Leufkens, H., & Martins, A. P. (2020). Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal. Diabetic Medicine, 37(4), 648-656. https://doi.org/10.1111/dme.14168
Liberti, L., McAuslane, N., Stolk, P., Breckenridge, A., & Leufkens, H. (2020). A Proposed Framework for a Globally Applicable Pragmatic Approach to Using Facilitated Regulatory Pathways. Therapeutic Innovation & Regulatory Science, 54(1), 55-68. https://doi.org/10.1007/s43441-019-00029-x
Weesie, Y. M., Hek, K., Schermer, T. R. J., Schellevis, F. G., Leufkens, H. G. M., Rook, E. J., & van Dijk, L. (2020). Use of Opioids Increases With Age in Older Adults: An Observational Study (2005-2017). Frontiers in Pharmacology, 11, 648. https://doi.org/10.3389/fphar.2020.00648
Aguiar, J. P., Bernardo, C., Gama Marques, J., Leufkens, H., & Alves da Costa, F. (2020). Identification of a Set of Patient-Related Features to Foster Safe Prescribing of Specific Antipsychotics in the Elderly With Dementia. Frontiers in Psychiatry, 11, [604201]. https://doi.org/10.3389/fpsyt.2020.604201
Atikeler, E. K., Leufkens, H. G. M. B., & Goettsch, W. (2020). Access to medicines in Turkey: Evaluation of the process of medicines brought from abroad. International Journal of Technology Assessment in Health Care, 36(6), 585-591. https://doi.org/10.1017/S0266462320000872
Vreman, R. A., Leufkens, H. G. M., & Kesselheim, A. S. (2020). Getting the Right Evidence After Drug Approval. Frontiers in Pharmacology, 11, [569535]. https://doi.org/10.3389/fphar.2020.569535
Vreman, R. A., Mantel-Teeuwisse, A. K., Hövels, A. M., Leufkens, H. G. M., & Goettsch, W. G. (2020). Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations. Value in Health, 23(1), 10-16. https://doi.org/10.1016/j.jval.2019.07.017
Vreman, R. A., Naci, H., Goettsch, W. G., Mantel-Teeuwisse, A. K., Schneeweiss, S. G., Leufkens, H. G. M., & Kesselheim, A. S. (2020). Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 108(2), 350-357. https://doi.org/10.1002/cpt.1835
Vreman, R. A., de Ruijter, A. S., Zawada, A., Tafuri, G., Stoyanova-Beninska, V., O'Connor, D., Naumann-Winter, F., Wolter, F., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., Sidiropoulos, I., Larsson, K., & Goettsch, W. G. (2020). Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations. Drug Discovery Today, 25(7), 1223-1231. https://doi.org/10.1016/j.drudis.2020.04.012
Vreman, R. A., Belitser, S. V., Mota, A. T. M., Hövels, A. M., Goettsch, W. G., Roes, K. C. B., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2020). Efficacy gap between phase II and subsequent phase III studies in oncology. British Journal of Clinical Pharmacology, 86(7), 1306-1313. https://doi.org/10.1111/bcp.14237
2016
Wetenschappelijke publicaties
Dalem, J. V., Brouwers, M., Stehouwer, C., Krings, A., Leufkens, H. G. M., Driessen, J. H. M., Vries, F. D., & Burden, A. (2016). Het risico op hypoglykemieën bij sulfonylureumderivaten ten opzichte van metformine in relatie tot nierfunctie en metabolietgroep. Nederlands Platform voor Farmaceutisch Onderzoek.
2015
Wetenschappelijke publicaties
Klop, C., Gibson-Smith, D., Elders, P. J. M., Welsing, P. M. J., Leufkens, H. G. M., Harvey, N. C., Bijlsma, J. W. J., van Staa, T-P., & de Vries, F. (2015). Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000–2010. Osteoporosis International. https://doi.org/10.1007/s00198-015-3098-x
Eichler, H-G., Baird, L. G., Barker, R., Bloechl-Daum, B., Børlum-Kristensen, F., Brown, J., Chua, R., Del Signore, S., Dugan, U., Ferguson, J., Garner, S., Goettsch, W., Haigh, J., Honig, P., Hoos, A., Huckle, P., Kondo, T., Le Cam, Y., Leufkens, H., ... Hirsch, G. (2015). From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clinical Pharmacology and Therapeutics, 97(3), 234-46. https://doi.org/10.1002/cpt.59
2014
Wetenschappelijke publicaties
Klop, C., Gibson-Smith, D., Elders, P. J. M., van Schoor, N., Welsing, P. M. J., Leufkens, H. G. M., Harvey, N. C., van Staa, T. P., & de Vries, F. (2014). The Risk of Major and Any (non-Hip) Fracture after Hip Fracture in the United Kingdom: 2000-2010. Pharmacoepidemiology and Drug Safety.
Gibson-Smith, D., Klop, C., Elders, P. J., Welsing, P. M., van Schoor, N., Leufkens, H. G., Harvey, N. C., van Staa, T. P., & de Vries, F. (2014). The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000-2010. Osteoporosis International. https://doi.org/10.1007/s00198-014-2799-x
2013
Wetenschappelijke publicaties
Klop, C., de Vries, F., Lalmohamed, A., Leufkens, B., Bijlsma, J. W. J., & Welsing, P. M. J. (2013). Risk of myocardial infarction in Dutch patients following discharge for total hip/knee replacement and matched controls: a population-based cohort study. OA Epidemiology, 1-8.
Abbing-Karahagopian, V., Huerta, C., Souverein, P. C., de Abajo, F., Leufkens, H. G. M., Slattery, J., Alvarez, Y., Montserrat, M., Gil, M., Hesse, U., Requena, G., de Vries, F., Rottenkolber, M., Schmiedl, S., Reynolds, R., Schlinger, R., de Groot, M., Klungel, O. H., van Staa, T. P., ... De Bruin, M. L. (2013). Antidepressant Prescribing in Five European Countries: Application of Common Methods to Assess the Variation in Prevalence. Pharmacoepidemiology and Drug Safety.
Lalmohamed, A., Vestergaard, P., Javaid, M. K., de Boer, A., Leufkens, H. G., van Staa, T. P., & de Vries, F. (2013). Risk of gastrointestinal bleeding in patients undergoing total hip or knee replacement compared with matched controls: a nationwide cohort study. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2013.108
2012
Wetenschappelijke publicaties
Bazelier, M. T., Van Staa, T-P., Uitdehaag, B. M. J., Cooper, C., Leufkens, H. G. M., Vestergaard, P., Herings, R. M. C., & De Vries, F. (2012). Risk of fractures in patients with multiple sclerosis: A population-based cohort study. Neurology. https://doi.org/10.1212/WNL.0b013e318259e0ff
Bazelier, M. T., Vestergaard, P., Gallagher, A. M., van Staa, T. P., Cooper, C., Leufkens, H. G., & de Vries, F. (2012). Risk of Fracture with Thiazolidinediones: Disease or Drugs? Calcif Tissue Int. https://doi.org/10.1007/s00223-012-9591-8
Bazelier, M. T., De Vries, F., Bentzen, J., Vestergaard, P., Leufkens, H. G. M., Van Staa, T-P., & Koch-Henriksen, N. (2012). Incidence of fractures in patients with multiple sclerosis: The Danish National Health Registers. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458511426739
Lalmohamed, A., Bazelier, M. T., Van Staa, T. P., Uitdehaag, B. M., Leufkens, H. G., De Boer, A., & De Vries, F. (2012). Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2012.03668.x
Lalmohamed, A., Vestergaard, P., Cooper, C., de Boer, A., Leufkens, H. G., van Staa, T. P., & de Vries, F. (2012). Timing of stroke in patients undergoing total hip replacement and matched controls: a nationwide cohort study. Stroke. https://doi.org/10.1161/STROKEAHA.112.668509
Lalmohamed, A., Vestergaard, P., Klop, C., Grove, E. L., de Boer, A., Leufkens, H. G., van Staa, T. P., & de Vries, F. (2012). Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. JAMA Internal Medicine. https://doi.org/10.1001/archinternmed.2012.2713
Bazelier, M. T., Bentzen, J., Vestergaard, P., Stenager, E., Leufkens, H. G., van Staa, T. P., & de Vries, F. (2012). The risk of fracture in incident multiple sclerosis patients: The Danish National Health Registers. Mult Scler. https://doi.org/1352458512442755 [pii]
10.1177/1352458512442755
2011
Wetenschappelijke publicaties
Leufkens, H. G., Schellekens, H., & Aronsson, B. (2011). Post-innovation innovation of medicinal products. Drug Discovery Today: Technologies, 8(1), e37-e41. https://doi.org/10.1016/j.ddtec.2011.06.001
Pouwels, S., Lalmohamed, A., Souverein, P., Cooper, C., Veldt, B. J., Leufkens, H. G., De Boer, A., Van Staa, T., & De Vries, F. (2011). Use of proton pump inhibitors and risk of hip/femur fracture: A population-based case-control study. Osteoporosis International. https://doi.org/10.1007/s00198-010-1337-8
2010
Wetenschappelijke publicaties
Lalmohamed, A., Arden, N., van Staa, T., Leufkens, H., Bazelier, M., & de Vries, F. (2010). KNEE ARTHOPLASTY AND RISK OF HIP FRACTURE: A POPULATION-BASED CASE-CONTROL STUDY. Osteoporosis International.
2009
Wetenschappelijke publicaties
Stolk, P., Heemstra, H. E., Leufkens, H. G., Bloechl-Daum, B., & Heerdink, E. R. (2009). No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - A pilot study. Orphanet Journal of Rare Diseases, 4(1), [27]. https://doi.org/10.1186/1750-1172-4-27
Van Den Brand, M. W. M., Pouwels, S., Samson, M. M., Van Staa, T. P., Thio, B., Cooper, C., Leufkens, H. G. M., Egberts, A. C. G., Verhaar, H. J. J., & De Vries, F. (2009). Erratum: Use of anti-depressants and the risk of fracture of the hip or femur (Osteoporos Int (DOI 10.1007/s00198-009-0849-6)). Osteoporosis International. https://doi.org/10.1007/s00198-009-0921-2
Pouwels, S., Lalmohamed, A., Leufkens, B., De Boer, A., Cooper, C., Van Staa, T., & De Vries, F. (2009). Risk of hip/femur fracture after stroke: A population-based case-control study. Stroke. https://doi.org/10.1161/STROKEAHA.109.554055
Pouwels, S., Van Staa, T. P., Egberts, A. C. G., Leufkens, H. G. M., Cooper, C., & De Vries, F. (2009). Antipsychotic use and the risk of hip/femur fracture: A population-based case-control study. Osteoporosis International. https://doi.org/10.1007/s00198-008-0826-5
2008
Wetenschappelijke publicaties
Stolk, P., Schneeweiss, S., Leufkens, H. G. M., & Heerdink, E. R. (2008). Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives. Contraception, 78(5), 399-404. https://doi.org/10.1016/j.contraception.2008.06.009
2007
Wetenschappelijke publicaties
Florentinus, S. R., Van Hulten, R., Kloth, M. E. M., Heerdink, E. R., Griens, A. M. G. F., Leufkens, H. G. M., & Groenewegen, P. P. (2007). The effect of pharmacotherapy audit meetings on early new drug prescribing by general practitioners. Annals of Pharmacotherapy, 41(2), 319-324. https://doi.org/10.1345/aph.1H250
de Vries, F., Pouwels, S., Lammers, J. W. J., Leufkens, H. G. M., Bracke, M., Cooper, C., & van Staa, T. P. (2007). Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. Journal of Internal Medicine. https://doi.org/10.1111/j.1365-2796.2006.01754.x
2006
Wetenschappelijke publicaties
Van Staa, T. P., De Vries, F., & Leufkens, H. G. M. (2006). Gastric acid-suppressive agents and risk of Clostridium difficile-associated disease [1]. JAMA, 295(22), 2599. https://doi.org/10.1001/jama.295.22.2599-a
Florentinus, S. R., Van Hulten, R., Kramer, M., Van Dijk, L., Heerdink, E. R., Leufkens, H. G. M., & Groenewegen, P. P. (2006). Which pharmacists contribute to high-level pharmacotherapy audit meetings with general practitioners? Annals of Pharmacotherapy, 40(9), 1640-1646. https://doi.org/10.1345/aph.1H180
Wilting, I., De Vries, F., Thio, B. M. K. S., Cooper, C., Heerdink, E. R., Leufkens, H. G. M., Nolen, W. A., Egberts, A. C. G., & van Staa, T. P. (2006). The risk of fractures in patients currenly or previously using lithium. British Journal of Clinical Pharmacology.
2005
Wetenschappelijke publicaties
De Vries, F., Van Staa, T. P., Bracke, M. S. G. M., Cooper, C., Leufkens, H. G. M., & Lammers, J-WJ. (2005). Severity of obstructive airway disease increases the risk of osteoporotic fractures,Sterke obstructie luchtwegen verhoogt fractuurrisico. Pharmaceutisch Weekblad.
2003
Wetenschappelijke publicaties
Bouvy, M. L., Heerdink, E. R., Urquhart, J., Grobbee, D. E., Hoes, A. W., & Leufkens, H. G. M. (2003). Apotheker stimuleert correct gebruik lisdiuretica bij patiënten met hartfalen: Begeleiding verbetert therapietrouw. Pharmaceutisch Weekblad, 138(41), 1432-1439.
Vakpublicaties
Maussen, L. J., Bouvy, M. L., Smit, H., & Leufkens, B. G. M. (2003). Welke medicijnen worden besteld bij een internetapotheek? Vooraljonge vrouwen gaan virtueel. Pharmaceutisch Weekblad, 138(18), 630-633.
2002
Wetenschappelijke publicaties
Movig, K. L. L., Meijer, W. E. E., Heerdink, E. R., Leufkens, H. G. M., Egberts, A. C. G., Sewnath, M. E., & Gouma, D. J. (2002). Toegenomen peroperatief bloedverlies bij paroxetinegebruik. Nederlands Tijdschrift voor Geneeskunde, 146(52), 2564-2565.
2001
Wetenschappelijke publicaties
van Staa, TP., Wegman, S., deVries, F., Leufkens, B., & Cooper, C. (2001). Use of statins and risk of fractures (vol 285, pg 1850, 2001). JAMA.
Heerdink, E. R., Leufkens, H. G. M., Claessens, A. A. M. C., Lamers, C. B. H. W., & Van Eijk, J. T. M. (2001). Factors associated with non-response in proton pump inhibitor users: A study of lansoprazole therapy. Pharmacy World and Science, 23(3), 107-110. https://doi.org/10.1023/A:1011279426224
1995
Wetenschappelijke publicaties
Heerdink, E. R., Leufkens, H. G., Koppedraaijer, C., & Bakker, A. (1995). Information on drug use in the elderly: A comparison of pharmacy, general- practitioner and patient data. Pharmacy World & Science, 17(1), 20-24. https://doi.org/10.1007/BF01875554
1993
Wetenschappelijke publicaties
Heerdink, E. R., & Leufkens, H. G. (1993). COMPRESSIE EN CLUSTERING VAN GENEESMIDDELENGEBRUIK BIJ OUDEREN. Pharmaceutisch Weekblad, 128(49), 1492-1497.
1991
Wetenschappelijke publicaties
Petri, H., Heerdink, R., Leufkens, H. G., Kessels, F., & Urquhart, J. (1991). Channeling of antidepressant drugs to patients with cardiovascular disease. Post Marketing Surveillance, 5(2), 159-167.